Form 4: Apellis CFO Granted 58,140 RSUs, Vesting Over Four Years

Apellis Pharmaceuticals' CFO, Timothy Sullivan, received a grant of 58,140 Restricted Stock Units, vesting annually over four years.

Summary

• Timothy Eugene Sullivan, Chief Financial Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 58,140 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The RSU award was granted on January 28, 2026, and vests 25% annually over four years from the grant date, contingent upon continued service.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Mr. Sullivan directly beneficially owns 152,041 shares of Common Stock.
• Additionally, 60,396 shares are indirectly held by The Timothy E Sullivan Irrevocable Trust of 2023, for which Mr. Sullivan disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It represents standard executive compensation, aligning management incentives with shareholder interests and aiding retention, without indicating any new fundamental business developments.

Positives

• The RSU grant aligns the Chief Financial Officer's long-term incentives with shareholder interests, encouraging sustained performance.
• The four-year vesting schedule promotes executive retention, ensuring continuity in key leadership roles.

Negatives

• The issuance of new RSUs, upon vesting, will result in a minor dilutive effect on existing shareholders, though this is standard for equity compensation.

Future Outlook

The RSU award granted to the CFO is structured to vest 25% annually over four years from the grant date of January 28, 2026, subject to continued service, indicating a long-term incentive structure.

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units (RSUs) with multi-year vesting schedules is a common practice in the biotechnology and pharmaceutical industries for executive compensation. This approach is widely used to attract, retain, and motivate key personnel by aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The RSU grant to Apellis's CFO, with a four-year annual vesting schedule, is consistent with typical executive compensation structures observed across the biotechnology and pharmaceutical sectors.
• Companies like Moderna (MRNA) and BioNTech (BNTX) frequently utilize similar long-term equity incentives to retain top talent and ensure management commitment to strategic goals.
• The grant size of 58,140 units, while specific to Apellis, falls within the expected range for a Chief Financial Officer at a publicly traded biopharmaceutical company, reflecting standard practices for aligning executive compensation with company size and market capitalization.

Stakeholder Impact

• Shareholders: Experience minor dilution upon vesting of RSUs, but benefit from enhanced executive retention and alignment of management incentives with long-term company performance.
• Employees: The RSU grant to the CFO reinforces the company's commitment to competitive executive compensation, potentially boosting morale and demonstrating a stable leadership team.

Next Steps

• The granted Restricted Stock Units will vest 25% annually over the next four years, starting from January 28, 2026, subject to Timothy Sullivan's continued service.

Key Dates

Recommendation

This Form 4 filing reports a standard RSU grant to the CFO, which is a routine compensation event. It does not provide new fundamental information that would warrant a change in investment thesis. The grant aligns executive incentives with long-term shareholder value but does not signal immediate operational or financial shifts.

Keywords

Apellis Pharmaceuticals, APLS, Restricted Stock Units, RSU grant, CFO compensation, executive compensation, insider transaction, Form 4, equity award, vesting schedule